Importance of ALT levels of >30 in patients with MASLD: Nara Declaration 2023

DOI Web Site 4 References
  • Kawanaka Miwa
    Department of General Internal Medicine 2, Kawasaki Medical Center, Kawasaki Medical School
  • Fujii Hideki
    Department of Hepatology, Graduate School of Medicine, Osaka Metropolitan University
  • Iwaki Michihiro
    Department of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine
  • Hayashi Hideki
    Department of Gastroenterology and Hepatology, Gifu Municipal Hospital
  • Toyoda Hidenori
    Department of Gastroenterology and Hepatology, Ogaki Municipal Hospital
  • Oeda Satoshi
    Liver Center, Saga University Hospital
  • Hyogo Hideyuki
    Hyogo Life Care Clinic
  • Morishita Asahiro
    Department of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University
  • Munekage Kensuke
    Department of Gastroenterology, Kochi Prefectural Hata Kenmin Hospital
  • Kawata Kazuhito
    Hepatology Division, Department of Internal Medicine II, Hamamatsu University School of Medicine
  • Tsutsumi Tsubasa
    Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine
  • Sawada Koji
    Division of Gastroenterology, Department of Internal Medicine, Asahikawa Medical University
  • Maeshiro Tatsuji
    Department of Gastroenterology, Urasoe General Hospital
  • Tobita Hiroshi
    Department of Hepatology, Shimane University Hospital
  • Yoshida Yuichi
    Department of Gastroenterology and Hepatology, Suita Municipal Hospital
  • Naito Masafumi
    Department of Gastroenterology and Hepatology, Suita Municipal Hospital
  • Araki Asuka
    Division of Pathology, Shimane University Hospital
  • Arakaki Shingo
    First Department of Internal Medicine, University of the Ryukyus Hospital
  • Kawaguchi Takumi
    Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine
  • Noritake Hidenao
    Hepatology Division, Department of Internal Medicine II, Hamamatsu University School of Medicine
  • Ono Masafumi
    Division of Innovative Medicine for Hepatobiliary & Pancreatology, Faculty of Medicine, Kagawa University
  • Masaki Tsutomu
    Department of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University
  • Yasuda Satoshi
    Department of Gastroenterology and Hepatology, Ogaki Municipal Hospital
  • Tomita Eiichi
    Department of Gastroenterology and Hepatology, Gifu Municipal Hospital
  • Yoneda Masato
    Department of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine
  • Tokushige Akihiro
    Department of Clinical Pharmacology and Therapeutics School of Medicine, University of the Ryukyus
  • Kamada Yoshihiro
    Department of Advanced Metabolic Hepatology, Osaka University, Graduate School of Medicine
  • Takahashi Hirokazu
    Liver Center, Saga University Hospital
  • Ueda Shinichiro
    Department of Clinical Pharmacology and Therapeutics School of Medicine, University of the Ryukyus
  • Aishima Shinichi
    Department of Scientific Pathology Graduate School of Medical Sciences, Kyushu University
  • Sumida Yoshio
    Graduate School of Healthcare Management, International University of Healthcare and Welfare
  • Okanoue Takeshi
    Department of Gastroenterology and Hepatology, Saiseikai Suita Hospital
  • Nakajima Atsushi
    Department of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine
  • Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD)

Bibliographic Information

Other Title
  • 奈良宣言（ALT over 30）のMASLD（metabolic dysfunction-associated steatotic liver disease）における臨床的意義の検証

Abstract

<p>The Nara Declaration 2023 recommends that patients with ALT levels of >30 U/L and those who have steatosis, diabetes, hypertension, and/or dyslipidemia should be referred to a hepatologist, considering the results of the FIB4 index and/or platelet count. ALT levels of >30 U/L is a simple and useful indicator and, when combined with the FIB4 index and platelet count, can detect MASLD cases that require further treatment and follow-up. Moreover, among patients with MAFLD and ALT levels of ≤30 U/L, the FIB4 index may be useful for identifying those at risk of MASLD. The Nara Declaration 2023 is an important and convenient guideline that provides primary care doctors with specific indications for referral to a hepatologist. When combined with the FIB4 index, ALT levels of >30 U/L is expected to predict high-risk MASLD cases.</p>

Journal

  • Kanzo

    Kanzo 65 (4), 186-191, 2024-04-01

    The Japan Society of Hepatology

References(4)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top